





an Open Access Journal by MDPI

Peptide-Based Drug Development

Guest Editors:

Prof. Dr. William D. Lubell

Department of Chemistry, Université de Montréal, Montréal, QC H2V 0B3, Canada

Prof. Jackie Wilce

Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Melbourne, Australia

Dr. Johan Rosengren

School of Biomedical Sciences, Faculty of Medicine, University of Oueensland, Brisbane, Australia

Deadline for manuscript submissions:

closed (31 May 2022)

Message from the Guest Editors

Dear Colleagues,

Peptides and their analogs are readily accessible by chemical and biological methods. With ideal properties for forming high affinity and specific interactions with target protein surfaces, they have established an important niche in the drug development spectrum complementing small molecule and biological therapeutics. Among the most successful biomedicines in use today, peptide-based drugs show great promise for the future. The theme issue "Peptide-Based Drug Development" invites contributions across the spectrum of advances, including novel bioactive peptides, library-based peptide lead discovery, and chemistry for improving peptide pharmacokinetic (ADMET) properties.

Prof. Dr. William D. Lubell Assoc. Prof. Jackie Wilce Dr. Johan Rosengren Guest Editors













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us